YBioA4001

YBioA4001 is a biosimilar drug candidate being developed by Yerlika Biopharma for gynecological indications. Currently in the preclinical stage of development, the company has successfully manufactured three validation batches of both the active pharmaceutical ingredient (API) and the finished drug product (Fill & Finish). The medication is designed for injectable administration and is being developed in both pen and vial delivery formats. Yerlika Biopharma expects to submit the regulatory dossier for the product in the first quarter of 2027, with an anticipated market approval date in 2028. While the specific reference biologic has not been officially disclosed, the therapeutic focus and delivery methods are characteristic of recombinant hormones used in assisted reproductive technology and other gynecological treatments.